Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma — Stella

Home/Osteogenic Sarcoma Recurrent/

View on ClinicalTrials.gov

Recruiting

Back to Osteogenic Sarcoma Recurrent trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(2 sites)

United States

Hackensack University Medical Center, Hackensack, New Jersey

M.D. Anderson Children's Cancer Hospital, Houston, Texas

Key details

Phase

Safety & dosing

Sponsor

Hackensack Meridian Health

Collaborators

M.D. Anderson Cancer Center, Iscador AG, Arlesheim, Switzerland.

Enrollment target

~32 participants

Started

May 2024

Primary completion

May 2027

Age range

8 Years – 30 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.